Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
si-CAV2
- Development stage
- Unknown
- Lead developer
- Kagoshima University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral
01
Overview
si-CAV2 is a small interfering RNA (siRNA) designed to silence the expression of the caveolin-2 (CAV2) gene. In the context of oncology research, specifically renal cell carcinoma (RCC), si-CAV2 is used as a tool to investigate the role of CAV2 in tumor progression. Studies have shown that CAV2 is a direct target of the tumor-suppressive microRNA miR-218 and is often upregulated in RCC clinical specimens. By silencing CAV2, researchers observed a significant inhibition of cancer cell migration and invasion, suggesting that CAV2 contributes to metastatic processes through the regulation of focal adhesion and tight junction pathways. The drug acts via the RNA interference (RNAi) pathway, where it mediates the sequence-specific degradation of CAV2 mRNA, thereby preventing the translation of the CAV2 protein.
- Other names
- caveolin-2 siRNAcaveolin2 siRNAcaveolin 2 siRNAsiRNA targeting CAV2
02
Targets
CaV (Voltage-gated calcium channel protein complex)
Beyond the preview
Go deeper on si-CAV2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on si-CAV2.